Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
58
HAE Quote, Financials, Valuation and Earnings
Last price:
$80.16
Seasonality move
:
0.35%
Day range:
$79.87 - $81.27
52-week range:
$47.32 - $87.32
Dividend yield:
0%
P/E ratio:
23.38x
P/S ratio:
2.96x
P/B ratio:
4.42x
Volume:
336.9K
Avg. volume:
745.7K
1-year change:
2.65%
Market cap:
$3.8B
Revenue:
$1.4B
EPS (TTM):
$3.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$331.9M | $1.25 | -4.78% | 68.87% | $90.20 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.50 | 7.51% | -71.7% | $144.43 |
|
DXCM
DexCom, Inc.
|
$1.2B | $0.65 | 11.43% | 70.31% | $85.27 |
|
MASI
Masimo Corp.
|
$407.6M | $1.46 | -32.15% | 565.51% | $183.75 |
|
SOLV
Solventum Corp.
|
$2B | $1.49 | -5.45% | 768.77% | $85.64 |
|
XRAY
Dentsply Sirona, Inc.
|
$924.6M | $0.29 | 2.17% | 234.18% | $12.77 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$80.15 | $90.20 | $3.8B | 23.38x | $0.00 | 0% | 2.96x |
|
ABT
Abbott Laboratories
|
$125.29 | $144.43 | $217.9B | 15.72x | $0.59 | 1.88% | 5.00x |
|
DXCM
DexCom, Inc.
|
$66.37 | $85.27 | $25.9B | 36.94x | $0.00 | 0% | 5.99x |
|
MASI
Masimo Corp.
|
$130.06 | $183.75 | $7B | 116.80x | $0.00 | 0% | 4.11x |
|
SOLV
Solventum Corp.
|
$79.24 | $85.64 | $13.7B | 9.12x | $0.00 | 0% | 1.65x |
|
XRAY
Dentsply Sirona, Inc.
|
$11.43 | $12.77 | $2.3B | -- | $0.16 | 5.6% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
59.05% | -0.136 | 53.75% | 0.93x |
|
ABT
Abbott Laboratories
|
20.25% | 0.321 | 5.99% | 1.12x |
|
DXCM
DexCom, Inc.
|
48.58% | 1.837 | 9.81% | 1.33x |
|
MASI
Masimo Corp.
|
41.99% | 0.887 | 7.4% | 1.68x |
|
SOLV
Solventum Corp.
|
50.75% | 0.850 | 40.57% | 0.94x |
|
XRAY
Dentsply Sirona, Inc.
|
62.66% | 1.610 | 97.97% | 0.73x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$183.4M | $67.3M | 7.99% | 19.39% | 20.56% | $106.3M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
DXCM
DexCom, Inc.
|
$747.4M | $242.5M | 14.67% | 30.94% | 20.05% | $579.4M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
SOLV
Solventum Corp.
|
$1.1B | $171M | 13.6% | 42.2% | 8.16% | -$21M |
|
XRAY
Dentsply Sirona, Inc.
|
$441M | $49M | -20.14% | -44.58% | 5.42% | $40M |
Haemonetics Corp. vs. Competitors
-
Which has Higher Returns HAE or ABT?
Abbott Laboratories has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 14.07%. Haemonetics Corp.'s return on equity of 19.39% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About HAE or ABT?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.54%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.28%. Given that Abbott Laboratories has higher upside potential than Haemonetics Corp., analysts believe Abbott Laboratories is more attractive than Haemonetics Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 ABTAbbott Laboratories15 7 0 -
Is HAE or ABT More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.854%.
-
Which is a Better Dividend Stock HAE or ABT?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.88% to investors and pays a quarterly dividend of $0.59 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HAE or ABT?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. Haemonetics Corp.'s net income of $38.7M is lower than Abbott Laboratories's net income of $1.6B. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.38x while Abbott Laboratories's PE ratio is 15.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.96x versus 5.00x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.96x 23.38x $327.3M $38.7M ABTAbbott Laboratories5.00x 15.72x $11.4B $1.6B
-
Which has Higher Returns HAE or DXCM?
DexCom, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 23.47%. Haemonetics Corp.'s return on equity of 19.39% beat DexCom, Inc.'s return on equity of 30.94%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B DXCMDexCom, Inc.61.8% $0.70 $5.3B -
What do Analysts Say About HAE or DXCM?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.54%. On the other hand DexCom, Inc. has an analysts' consensus of $85.27 which suggests that it could grow by 28.48%. Given that DexCom, Inc. has higher upside potential than Haemonetics Corp., analysts believe DexCom, Inc. is more attractive than Haemonetics Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 DXCMDexCom, Inc.20 4 0 -
Is HAE or DXCM More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.480, suggesting its more volatile than the S&P 500 by 48.047%.
-
Which is a Better Dividend Stock HAE or DXCM?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or DXCM?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than DexCom, Inc. quarterly revenues of $1.2B. Haemonetics Corp.'s net income of $38.7M is lower than DexCom, Inc.'s net income of $283.8M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.38x while DexCom, Inc.'s PE ratio is 36.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.96x versus 5.99x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.96x 23.38x $327.3M $38.7M DXCMDexCom, Inc.5.99x 36.94x $1.2B $283.8M
-
Which has Higher Returns HAE or MASI?
Masimo Corp. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 14.46%. Haemonetics Corp.'s return on equity of 19.39% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About HAE or MASI?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.54%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 41.28%. Given that Masimo Corp. has higher upside potential than Haemonetics Corp., analysts believe Masimo Corp. is more attractive than Haemonetics Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 MASIMasimo Corp.4 3 0 -
Is HAE or MASI More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.337%.
-
Which is a Better Dividend Stock HAE or MASI?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or MASI?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Haemonetics Corp.'s net income of $38.7M is lower than Masimo Corp.'s net income of $53.7M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.38x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.96x versus 4.11x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.96x 23.38x $327.3M $38.7M MASIMasimo Corp.4.11x 116.80x $371.5M $53.7M
-
Which has Higher Returns HAE or SOLV?
Solventum Corp. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 60.4%. Haemonetics Corp.'s return on equity of 19.39% beat Solventum Corp.'s return on equity of 42.2%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B SOLVSolventum Corp.53.91% $7.22 $10.1B -
What do Analysts Say About HAE or SOLV?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.54%. On the other hand Solventum Corp. has an analysts' consensus of $85.64 which suggests that it could grow by 8.07%. Given that Haemonetics Corp. has higher upside potential than Solventum Corp., analysts believe Haemonetics Corp. is more attractive than Solventum Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 SOLVSolventum Corp.3 7 1 -
Is HAE or SOLV More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HAE or SOLV?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or SOLV?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Solventum Corp. quarterly revenues of $2.1B. Haemonetics Corp.'s net income of $38.7M is lower than Solventum Corp.'s net income of $1.3B. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.38x while Solventum Corp.'s PE ratio is 9.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.96x versus 1.65x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.96x 23.38x $327.3M $38.7M SOLVSolventum Corp.1.65x 9.12x $2.1B $1.3B
-
Which has Higher Returns HAE or XRAY?
Dentsply Sirona, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of -47.35%. Haemonetics Corp.'s return on equity of 19.39% beat Dentsply Sirona, Inc.'s return on equity of -44.58%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B XRAYDentsply Sirona, Inc.48.78% -$2.14 $4B -
What do Analysts Say About HAE or XRAY?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.54%. On the other hand Dentsply Sirona, Inc. has an analysts' consensus of $12.77 which suggests that it could grow by 11.69%. Given that Haemonetics Corp. has higher upside potential than Dentsply Sirona, Inc., analysts believe Haemonetics Corp. is more attractive than Dentsply Sirona, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 XRAYDentsply Sirona, Inc.1 14 0 -
Is HAE or XRAY More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison Dentsply Sirona, Inc. has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.3%.
-
Which is a Better Dividend Stock HAE or XRAY?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona, Inc. offers a yield of 5.6% to investors and pays a quarterly dividend of $0.16 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Dentsply Sirona, Inc. pays out 13.85% of its earnings as a dividend. Dentsply Sirona, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HAE or XRAY?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Dentsply Sirona, Inc. quarterly revenues of $904M. Haemonetics Corp.'s net income of $38.7M is higher than Dentsply Sirona, Inc.'s net income of -$428M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.38x while Dentsply Sirona, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.96x versus 0.63x for Dentsply Sirona, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.96x 23.38x $327.3M $38.7M XRAYDentsply Sirona, Inc.0.63x -- $904M -$428M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
